ConductScience.org, home

Comparison · NCT02363322-48c2cce5

B/Current Standard of Care Plus ZMapp vs A/Current Standard of Care Alone: Mortality

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. B/Current Standard of Care Plus ZMapp vs A/Current Standard of Care Alone: Mortality. Trial comparisons, record NCT02363322-48c2cce5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02363322-48c2cce5

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2220.1170.381wilson
Risk in group 20.3710.2320.537wilson
Risk difference, group 1 minus group 2-0.149-0.3450.0622newcombe hybrid score
Risk ratio, group 1 over group 20.5980.2831.26log
Odds ratio, group 1 over group 20.4840.171.37log
Number needed to treat, for one fewer participant with the outcome on B/Current Standard of Care Plus ZMapp than on A/Current Standard of Care Alone6.7from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: standard of care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1B/Current Standard of Care Plus ZMapp
ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.~ZMApp: Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
836OG001
Group 2A/Current Standard of Care AloneOptimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting1335OG000

Outcome

Type
PRIMARY
Title
Mortality
Description
Death at Day 28
Time frame
28 days
Population
Seven of the eight deaths recorded in ZMapp recipients occurred before day 4, before the second of three planned infusions of ZMapp. The exception was one patient who received a second infusion on day 4 and died later that day. In the group that received the current standard of care alone, all 13 deaths occurred during the first 8 days of follow-up

Source ClinicalTrials.gov

Trial

Title
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
NCT number
NCT02363322
Phases
PHASE1, PHASE2
Conditions
Ebola Virus Infection
Interventions
B/Current Standard of Care Plus ZMapp, A/Current Standard of Care Alone
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Results first posted
2019-05-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02363322-48c2cce5